AbbVie and EvolveImmune Therapeutics have entered a strategic collaboration to advance immuno-oncology therapies aimed at overcoming resistance to current cancer treatments. This partnership will leverage EvolveImmune’s EVOLVE platform, which enhances T-cell engagement and co-stimulation, to create novel biotherapeutics for both solid and hematologic cancers. By focusing on targeted activation and reducing T-cell dysfunction, the EVOLVE platform aims to sustain the tumor-killing abilities of T-cells, addressing key therapeutic challenges in low-immunogenic tumors. Under the terms, AbbVie will provide $65 million in upfront fees and equity investment, with EvolveImmune eligible for up to $1.4 billion in milestone payments and royalties.
AbbVie, a leader in oncology, is dedicated to developing innovative treatments across challenging cancer types, including solid tumors and blood cancers, through advanced therapeutic platforms. With a portfolio of over 20 investigational medicines, AbbVie’s work spans from small molecules to multispecific antibodies and CAR-T therapies. EvolveImmune, backed by industry investors like Pfizer Ventures and Bristol Myers Squibb, is focused on pioneering multifunctional immunotherapies and plans to begin first-in-human trials in 2025. Leaders from both companies believe this collaboration will help bring groundbreaking solutions to patients with high unmet needs, validating EvolveImmune’s approach to transforming the standard of cancer care.
